Somatostatin analogues are drugs that stop your body from making too many hormones. Some neuroendocrine tumours (NETs) make large amounts of hormones that cause a group of symptoms called carcinoid syndrome. Somatostatin analogues are a possible treatment for people with carcinoid syndrome.
This report aims to provide a comprehensive presentation of the global market for Somatostatin Analogue Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Somatostatin Analogue Drug. This report contains market size and forecasts of Somatostatin Analogue Drug in global, including the following market information:
Global Somatostatin Analogue Drug Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Somatostatin Analogue Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Octreotide Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Somatostatin Analogue Drug include Camurus AB, Chiasma, Ipsen Group, Boehringer Ingelheim International GmbH, Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc. and Tarveda Therapeutics Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Somatostatin Analogue Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Somatostatin Analogue Drug Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Somatostatin Analogue Drug Market Segment Percentages, by Type, 2022 (%)
Octreotide
Lanreotide
Pasireotide
Global Somatostatin Analogue Drug Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Somatostatin Analogue Drug Market Segment Percentages, by Application, 2022 (%)
Acromegaly
Neuroendocrine Tumor (NET)
Others
Global Somatostatin Analogue Drug Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Somatostatin Analogue Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Somatostatin Analogue Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Somatostatin Analogue Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Camurus AB
Chiasma
Ipsen Group
Boehringer Ingelheim International GmbH
Eli Lilly & Co.
F. Hoffmann-La Roche Ltd.
Novartis AG
Pfizer Inc.
Tarveda Therapeutics Inc.
Teva Pharmaceutical Industries Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Somatostatin Analogue Drug, market overview.
Chapter 2: Global Somatostatin Analogue Drug market size in revenue.
Chapter 3: Detailed analysis of Somatostatin Analogue Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Somatostatin Analogue Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Somatostatin Analogue Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Somatostatin Analogue Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Somatostatin Analogue Drug Overall Market Size
2.1 Global Somatostatin Analogue Drug Market Size: 2022 VS 2030
2.2 Global Somatostatin Analogue Drug Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Somatostatin Analogue Drug Players in Global Market
3.2 Top Global Somatostatin Analogue Drug Companies Ranked by Revenue
3.3 Global Somatostatin Analogue Drug Revenue by Companies
3.4 Top 3 and Top 5 Somatostatin Analogue Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Somatostatin Analogue Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Somatostatin Analogue Drug Players in Global Market
3.6.1 List of Global Tier 1 Somatostatin Analogue Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Somatostatin Analogue Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Somatostatin Analogue Drug Market Size Markets, 2022 & 2030
4.1.2 Octreotide
4.1.3 Lanreotide
4.1.4 Pasireotide
4.2 By Type - Global Somatostatin Analogue Drug Revenue & Forecasts
4.2.1 By Type - Global Somatostatin Analogue Drug Revenue, 2018-2023
4.2.2 By Type - Global Somatostatin Analogue Drug Revenue, 2024-2030
4.2.3 By Type - Global Somatostatin Analogue Drug Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Somatostatin Analogue Drug Market Size, 2022 & 2030
5.1.2 Acromegaly
5.1.3 Neuroendocrine Tumor (NET)
5.1.4 Others
5.2 By Application - Global Somatostatin Analogue Drug Revenue & Forecasts
5.2.1 By Application - Global Somatostatin Analogue Drug Revenue, 2018-2023
5.2.2 By Application - Global Somatostatin Analogue Drug Revenue, 2024-2030
5.2.3 By Application - Global Somatostatin Analogue Drug Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Somatostatin Analogue Drug Market Size, 2022 & 2030
6.2 By Region - Global Somatostatin Analogue Drug Revenue & Forecasts
6.2.1 By Region - Global Somatostatin Analogue Drug Revenue, 2018-2023
6.2.2 By Region - Global Somatostatin Analogue Drug Revenue, 2024-2030
6.2.3 By Region - Global Somatostatin Analogue Drug Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Somatostatin Analogue Drug Revenue, 2018-2030
6.3.2 US Somatostatin Analogue Drug Market Size, 2018-2030
6.3.3 Canada Somatostatin Analogue Drug Market Size, 2018-2030
6.3.4 Mexico Somatostatin Analogue Drug Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Somatostatin Analogue Drug Revenue, 2018-2030
6.4.2 Germany Somatostatin Analogue Drug Market Size, 2018-2030
6.4.3 France Somatostatin Analogue Drug Market Size, 2018-2030
6.4.4 U.K. Somatostatin Analogue Drug Market Size, 2018-2030
6.4.5 Italy Somatostatin Analogue Drug Market Size, 2018-2030
6.4.6 Russia Somatostatin Analogue Drug Market Size, 2018-2030
6.4.7 Nordic Countries Somatostatin Analogue Drug Market Size, 2018-2030
6.4.8 Benelux Somatostatin Analogue Drug Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Somatostatin Analogue Drug Revenue, 2018-2030
6.5.2 China Somatostatin Analogue Drug Market Size, 2018-2030
6.5.3 Japan Somatostatin Analogue Drug Market Size, 2018-2030
6.5.4 South Korea Somatostatin Analogue Drug Market Size, 2018-2030
6.5.5 Southeast Asia Somatostatin Analogue Drug Market Size, 2018-2030
6.5.6 India Somatostatin Analogue Drug Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Somatostatin Analogue Drug Revenue, 2018-2030
6.6.2 Brazil Somatostatin Analogue Drug Market Size, 2018-2030
6.6.3 Argentina Somatostatin Analogue Drug Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Somatostatin Analogue Drug Revenue, 2018-2030
6.7.2 Turkey Somatostatin Analogue Drug Market Size, 2018-2030
6.7.3 Israel Somatostatin Analogue Drug Market Size, 2018-2030
6.7.4 Saudi Arabia Somatostatin Analogue Drug Market Size, 2018-2030
6.7.5 UAE Somatostatin Analogue Drug Market Size, 2018-2030
7 Somatostatin Analogue Drug Companies Profiles
7.1 Camurus AB
7.1.1 Camurus AB Company Summary
7.1.2 Camurus AB Business Overview
7.1.3 Camurus AB Somatostatin Analogue Drug Major Product Offerings
7.1.4 Camurus AB Somatostatin Analogue Drug Revenue in Global Market (2018-2023)
7.1.5 Camurus AB Key News & Latest Developments
7.2 Chiasma
7.2.1 Chiasma Company Summary
7.2.2 Chiasma Business Overview
7.2.3 Chiasma Somatostatin Analogue Drug Major Product Offerings
7.2.4 Chiasma Somatostatin Analogue Drug Revenue in Global Market (2018-2023)
7.2.5 Chiasma Key News & Latest Developments
7.3 Ipsen Group
7.3.1 Ipsen Group Company Summary
7.3.2 Ipsen Group Business Overview
7.3.3 Ipsen Group Somatostatin Analogue Drug Major Product Offerings
7.3.4 Ipsen Group Somatostatin Analogue Drug Revenue in Global Market (2018-2023)
7.3.5 Ipsen Group Key News & Latest Developments
7.4 Boehringer Ingelheim International GmbH
7.4.1 Boehringer Ingelheim International GmbH Company Summary
7.4.2 Boehringer Ingelheim International GmbH Business Overview
7.4.3 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Major Product Offerings
7.4.4 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue in Global Market (2018-2023)
7.4.5 Boehringer Ingelheim International GmbH Key News & Latest Developments
7.5 Eli Lilly & Co.
7.5.1 Eli Lilly & Co. Company Summary
7.5.2 Eli Lilly & Co. Business Overview
7.5.3 Eli Lilly & Co. Somatostatin Analogue Drug Major Product Offerings
7.5.4 Eli Lilly & Co. Somatostatin Analogue Drug Revenue in Global Market (2018-2023)
7.5.5 Eli Lilly & Co. Key News & Latest Developments
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 F. Hoffmann-La Roche Ltd. Company Summary
7.6.2 F. Hoffmann-La Roche Ltd. Business Overview
7.6.3 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Major Product Offerings
7.6.4 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue in Global Market (2018-2023)
7.6.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.7 Novartis AG
7.7.1 Novartis AG Company Summary
7.7.2 Novartis AG Business Overview
7.7.3 Novartis AG Somatostatin Analogue Drug Major Product Offerings
7.7.4 Novartis AG Somatostatin Analogue Drug Revenue in Global Market (2018-2023)
7.7.5 Novartis AG Key News & Latest Developments
7.8 Pfizer Inc.
7.8.1 Pfizer Inc. Company Summary
7.8.2 Pfizer Inc. Business Overview
7.8.3 Pfizer Inc. Somatostatin Analogue Drug Major Product Offerings
7.8.4 Pfizer Inc. Somatostatin Analogue Drug Revenue in Global Market (2018-2023)
7.8.5 Pfizer Inc. Key News & Latest Developments
7.9 Tarveda Therapeutics Inc.
7.9.1 Tarveda Therapeutics Inc. Company Summary
7.9.2 Tarveda Therapeutics Inc. Business Overview
7.9.3 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Major Product Offerings
7.9.4 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue in Global Market (2018-2023)
7.9.5 Tarveda Therapeutics Inc. Key News & Latest Developments
7.10 Teva Pharmaceutical Industries Ltd.
7.10.1 Teva Pharmaceutical Industries Ltd. Company Summary
7.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
7.10.3 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Major Product Offerings
7.10.4 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue in Global Market (2018-2023)
7.10.5 Teva Pharmaceutical Industries Ltd. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Somatostatin Analogue Drug Market Opportunities & Trends in Global Market
Table 2. Somatostatin Analogue Drug Market Drivers in Global Market
Table 3. Somatostatin Analogue Drug Market Restraints in Global Market
Table 4. Key Players of Somatostatin Analogue Drug in Global Market
Table 5. Top Somatostatin Analogue Drug Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Somatostatin Analogue Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Somatostatin Analogue Drug Revenue Share by Companies, 2018-2023
Table 8. Global Companies Somatostatin Analogue Drug Product Type
Table 9. List of Global Tier 1 Somatostatin Analogue Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Somatostatin Analogue Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Somatostatin Analogue Drug Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Somatostatin Analogue Drug Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Somatostatin Analogue Drug Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Somatostatin Analogue Drug Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Somatostatin Analogue Drug Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Somatostatin Analogue Drug Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Somatostatin Analogue Drug Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Somatostatin Analogue Drug Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Somatostatin Analogue Drug Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Somatostatin Analogue Drug Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Somatostatin Analogue Drug Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Somatostatin Analogue Drug Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Somatostatin Analogue Drug Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Somatostatin Analogue Drug Revenue, (US$, Mn), 2024-2030
Table 30. Camurus AB Company Summary
Table 31. Camurus AB Somatostatin Analogue Drug Product Offerings
Table 32. Camurus AB Somatostatin Analogue Drug Revenue (US$, Mn) & (2018-2023)
Table 33. Camurus AB Key News & Latest Developments
Table 34. Chiasma Company Summary
Table 35. Chiasma Somatostatin Analogue Drug Product Offerings
Table 36. Chiasma Somatostatin Analogue Drug Revenue (US$, Mn) & (2018-2023)
Table 37. Chiasma Key News & Latest Developments
Table 38. Ipsen Group Company Summary
Table 39. Ipsen Group Somatostatin Analogue Drug Product Offerings
Table 40. Ipsen Group Somatostatin Analogue Drug Revenue (US$, Mn) & (2018-2023)
Table 41. Ipsen Group Key News & Latest Developments
Table 42. Boehringer Ingelheim International GmbH Company Summary
Table 43. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product Offerings
Table 44. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue (US$, Mn) & (2018-2023)
Table 45. Boehringer Ingelheim International GmbH Key News & Latest Developments
Table 46. Eli Lilly & Co. Company Summary
Table 47. Eli Lilly & Co. Somatostatin Analogue Drug Product Offerings
Table 48. Eli Lilly & Co. Somatostatin Analogue Drug Revenue (US$, Mn) & (2018-2023)
Table 49. Eli Lilly & Co. Key News & Latest Developments
Table 50. F. Hoffmann-La Roche Ltd. Company Summary
Table 51. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product Offerings
Table 52. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue (US$, Mn) & (2018-2023)
Table 53. F. Hoffmann-La Roche Ltd. Key News & Latest Developments
Table 54. Novartis AG Company Summary
Table 55. Novartis AG Somatostatin Analogue Drug Product Offerings
Table 56. Novartis AG Somatostatin Analogue Drug Revenue (US$, Mn) & (2018-2023)
Table 57. Novartis AG Key News & Latest Developments
Table 58. Pfizer Inc. Company Summary
Table 59. Pfizer Inc. Somatostatin Analogue Drug Product Offerings
Table 60. Pfizer Inc. Somatostatin Analogue Drug Revenue (US$, Mn) & (2018-2023)
Table 61. Pfizer Inc. Key News & Latest Developments
Table 62. Tarveda Therapeutics Inc. Company Summary
Table 63. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product Offerings
Table 64. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue (US$, Mn) & (2018-2023)
Table 65. Tarveda Therapeutics Inc. Key News & Latest Developments
Table 66. Teva Pharmaceutical Industries Ltd. Company Summary
Table 67. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product Offerings
Table 68. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue (US$, Mn) & (2018-2023)
Table 69. Teva Pharmaceutical Industries Ltd. Key News & Latest Developments
List of Figures
Figure 1. Somatostatin Analogue Drug Segment by Type in 2022
Figure 2. Somatostatin Analogue Drug Segment by Application in 2022
Figure 3. Global Somatostatin Analogue Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Somatostatin Analogue Drug Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Somatostatin Analogue Drug Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Somatostatin Analogue Drug Revenue in 2022
Figure 8. By Type - Global Somatostatin Analogue Drug Revenue Market Share, 2018-2030
Figure 9. By Application - Global Somatostatin Analogue Drug Revenue Market Share, 2018-2030
Figure 10. By Type - Global Somatostatin Analogue Drug Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Somatostatin Analogue Drug Revenue Market Share, 2018-2030
Figure 12. By Application - Global Somatostatin Analogue Drug Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Somatostatin Analogue Drug Revenue Market Share, 2018-2030
Figure 14. By Region - Global Somatostatin Analogue Drug Revenue Market Share, 2018-2030
Figure 15. By Country - North America Somatostatin Analogue Drug Revenue Market Share, 2018-2030
Figure 16. US Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Somatostatin Analogue Drug Revenue Market Share, 2018-2030
Figure 20. Germany Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 21. France Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Somatostatin Analogue Drug Revenue Market Share, 2018-2030
Figure 28. China Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 32. India Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Somatostatin Analogue Drug Revenue Market Share, 2018-2030
Figure 34. Brazil Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Somatostatin Analogue Drug Revenue Market Share, 2018-2030
Figure 37. Turkey Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Somatostatin Analogue Drug Revenue, (US$, Mn), 2018-2030
Figure 41. Camurus AB Somatostatin Analogue Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Chiasma Somatostatin Analogue Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Ipsen Group Somatostatin Analogue Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Eli Lilly & Co. Somatostatin Analogue Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Novartis AG Somatostatin Analogue Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Pfizer Inc. Somatostatin Analogue Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
